Up-regulating Autophagy by Targeting the Mtor-4Ebp1 Pathway: a Possible Mechanism for Improving Cardiac Function in Mice with Experimental Dilated Cardiomyopathy

Bo Jin,Haiming Shi,Jun Zhu,Bangwei Wu,Quzhen Geshang
DOI: https://doi.org/10.1186/s12872-020-01365-9
IF: 2.174
2020-01-01
BMC Cardiovascular Disorders
Abstract:Background: Autophagy plays a crucial role in the pathological process of cardiovascular diseases. However, little is known about the pathological mechanism underlying autophagy regulation in dilated cardiomyopathy (DCM). Methods: We explored whether up-regulating autophagy could improve cardiac function in mice with experimental DCM through the mTOR-4EBP1 pathway. Animal model of DCM was established in BALB/c mice by immunization with porcine cardiac myosin. Both up- or down-regulation of autophagy were studied by administration of rapamycin or 3-MA in parallel. Morphology, Western blotting, and echocardiography were applied to confirm the pathological mechanisms. Results: Autophagy was activated and autophagosomes were significantly increased in the rapamycin group. The collagen volume fraction (CVF) was decreased in the rapamycin group compared with the DCM group (9.21 +/- 0.82% vs 14.38 +/- 1.24%, P<0.01). The expression of p-mTOR and p-4EBP1 were significantly decreased in rapamycin-induced autophagy activation, while the levels were increased by down-regulating autophagy with 3-MA. In the rapamycin group, the LVEF and FS were significantly increased compared with the DCM group (54.12 +/- 6.48% vs 45.29 +/- 6.68%, P<0.01; 26.89 +/- 4.04% vs 22.17 +/- 2.82%, P<0.05). As the inhibitor of autophagy, 3-MA aggravated the progress of maladaptive cardiac remodeling and declined cardiac function in DCM mice. Conclusions: The study indicated a possible mechanism for improving cardiac function in mice with experimental DCM by up-regulating autophagy via the mTOR-4EBP1 pathway, which could be a promising therapeutic strategy for DCM.
What problem does this paper attempt to address?